News
BDXA
0.0000
0.00%
0.00
BD Partners with ChemoGLO to Advance Hazardous Drug Contamination Testing
Reuters · 3d ago
BD AND CHEMOGLO™ COLLABORATE TO EXPAND HAZARDOUS DRUG CONTAMINATION TESTING FOR HEALTH CARE FACILITIES AND LABORATORIES
Reuters · 3d ago
BD Launches New FACSDiscover A8 Cell Analyzers Globally
Reuters · 4d ago
BD EVP Michael Feld Reports Sale of Common Shares
Reuters · 5d ago
BD Files Initial Beneficial Ownership Statement for Director Robert Luther Huffines
Reuters · 5d ago
BD Files Initial Statement of Beneficial Ownership; Jacqueline Wright Named as Director
Reuters · 5d ago
DBAG Highlights Innovation and Sustainability at UNITY INNOVATION CIRCLE 2025
Reuters · 5d ago
BD Amends 8-K to Disclose Compensation for New Board Members
Reuters · 6d ago
BD: FILES FOR POTENTIAL MIXED SHELF OF UP TO $10 BLN - SEC FILING
Reuters · 11/25 22:53
BD Surgiphor Surgical Wound Irrigation System Receives CE Approval in Europe
Reuters · 11/24 11:50
BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors
Reuters · 11/17 21:30
BD Onclarity HPV Assay Receives WHO Prequalification
Reuters · 11/17 11:51
BD and MEDITECH Launch First U.S. EMR Infusion Interoperability at Duncan Regional Hospital
Reuters · 11/13 11:50
Director Bertram L. Scott Reports Sale of BD Common Shares
Reuters · 11/07 22:37
BD <BDX.N>: STIFEL CUTS TARGET PRICE TO $210 FROM $224
Reuters · 11/07 13:20
U.S. RESEARCH ROUNDUP-Blackline, Carmax, Expedia
Reuters · 11/07 06:57
BD <BDX.N>: PIPER SANDLER CUTS TARGET PRICE TO $190 FROM $200
Reuters · 11/07 05:49
BD <BDX.N>: JEFFERIES CUTS TARGET PRICE TO $215 FROM $257
Reuters · 11/07 05:34
BUZZ-Becton Dickinson falls after missing revenue estimates
Reuters · 11/06 12:23
Medical tech firm Becton Dickinson's Q4 revenue up 8.3%, adjusted EPS beats estimates
Reuters · 11/06 11:39
More
Webull provides a variety of real-time BDXA stock news. You can receive the latest news about BECTON DICKINSON through multiple platforms. This information may help you make smarter investment decisions.
About BDXA
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.